| Literature DB >> 29087515 |
P G Artini1, C Tatone2, S Sperduti3, M D'Aurora3,4, S Franchi3,4, G Di Emidio2, R Ciriminna5, M Vento6, C Di Pietro7, L Stuppia3,4, V Gatta3,4.
Abstract
STUDY QUESTION: Is the phosphoinositol 1,3-kinase/protein kinase B (PI3K/AKT) pathway expression profile in cumulus cells (CCs) a potential marker of oocyte competence and predictive of pregnancy outcome? SUMMARY ANSWER: Eleven genes (AKT1, ARHGEF7, BCL2L1, CCND1, E2F1, HRAS, KCNH2, PIK3C2A, SHC1, SOS1 and SPP1) in the PI3K/AKT pathway were significantly down-regulated in CCs from oocytes that went on to produce a pregnancy compared to CCs associated with a negative outcome. WHAT IS KNOWN ALREADY: The PI3K/AKT pathway plays a pivotal role in the interdependence and continuous feedback between the oocyte and CCs. STUDY DESIGN SIZE, DURATION: The expression analysis of 92 transcripts in the PI3K/AKT pathway in CCs from patients with negative or positive pregnancy outcome, after single embryo transfer, was performed. Mouse CCs target gene expression was conducted to associate the expression profile of PI3K/AKT pathway to oocyte developmental profile. PARTICIPANTS/MATERIALS, SETTING,Entities:
Keywords: Oocyte competence; PI3K/AKT; cumulus cells; embryo; gene expression; pregnancy outcome
Mesh:
Substances:
Year: 2017 PMID: 29087515 PMCID: PMC5850344 DOI: 10.1093/humrep/dex320
Source DB: PubMed Journal: Hum Reprod ISSN: 0268-1161 Impact factor: 6.918
Figure 1Experimental design. The flowchart depicts the experimental design of the study including the number of samples enroled, stimulation protocol used and patient inclusion criteria. CCs, cumulus cells.
Patient demographics and baseline characteristics. Data are presented as mean ± SD.
| Group 1 positive | Group 2 negative | ||
|---|---|---|---|
| No. of patients | 6 | 10 | |
| Age (y) | 33.1 ± 1.8 | 34.1 ± 1.0 | NS |
| Duration of infertility (y) | 3.1 ± 0.8 | 2.9 ± 1.2 | NS |
| Basal FSH (mU/ml) | 5.2 ± 1.5 | 4.9 ± 1.4 | NS |
| AFC | 16.4 ± 2.1 | 15.5 ± 3.1 | NS |
| Treatment length (d) | 11.5 ± 1.5 | 11.7 ± 1.9 | NS |
| Total gonadotropin dose (IU) | 2565 ± 1000 | 2650 ± 1125 | NS |
| E2 on hCGhCG-day (pg/ml) | 1435.4 ± 480 | 1515.5 ± 540 | NS |
| No. of oocytes collected | 11.3 ± 2.8 | 10.6 ± 2.5 | NS |
AFC, antral follicle count; E2, estradiol.
aStudent t-test. NS, not statistically significant (P > 0.05).
Figure 2Genes down-regulated in CCs associated with positive versus negative outcome. Bar charts show the 11 transcripts down-expressed in CCs associated with positive outcome versus negative outcome (control) ± SD. Raw data were analysed by DataAssist software under global normalization using GAPDH, 18 s and GUSB as selected internal controls. A gene was considered differentially expressed in positive CCs versus negative CCs when showing a fold change >1.4 or <0.7 and a P-value < 0.05 (ANOVA). P-values were adjusted using Benjamini–Hochberg FDR correction.
Figure 3qRT-PCR for Akt1, Bcl2l1 and Shc in mouse CCs from oocytes at different maturation stages after hCG administration. (A) The curve draws the oocytes maturation profile after hCG administration. 12–15 h post-hCG (arrow) represents the optimal maturation window, 9 h represents the immature oocyte and 21–24 h the post maturation stage. (B) Relative Fold Change of Akt1 gene. (C) Relative Fold Change of Bcl2l1 gene. (D) Relative Fold Change of Shc1. Fold changes are calculated using ΔΔCt method to compare mRNA levels between samples (12, 15, 21, 24 h post-hCG) and control (9 h post-hCG). ANOVA test was used to assess the P-value, considering data significant when P < 0.05 (*P < 0.05, **P < 0.005).
Figure 4qRT-PCR ESR1, FOXO1, FOXO3 and FOXO4 human CCs from oocytes leading to a positive outcome versus a negative outcome. (A) Relative fold change of ESR1 gene. (B) Relative fold change of FOXO1 gene. (C) Relative fold change of FOXO3 gene. (D) Relative fold change of FOXO4 gene. ANOVA test was used to assess the P-value, considering data significant when P < 0.05 (*P < 0.05).
Figure 5qRT-PCR for Esr1, Foxo1, Foxo3 and Foxo4 in mouse CCs from oocytes at different maturation stages after hCG administration. (A) Relative Fold Change of Esr1 gene. (B) Relative Fold Change of Foxo1 gene. (C) Relative Fold Change of Foxo3 gene. (D) Relative Fold Change of Foxo4 gene. ANOVA test was used to assess the P-values, considering data significant when P < 0.05 (*P < 0.05).
Figure 6IPA-inferred network analysis for the 11 genes down-regulated in CCs from oocytes leading to a positive outcome versus a negative outcome. IPA-inferred network analysis of the 11 genes revealed one network with a score = 33 centred around oestrogen receptor ERβ (central node). IPA upstream regulators analysis predicted a down-regulation of ERβ expression (z-score −0.644, P-value < 4.01E-07) as the driving molecule of the reported changes in our data set.
The 11 transcripts down-regulated in CCs from the positive outcome group compared to CCs in the negative outcome group.
| Symbol | Entrez gene name | Fold change | Location | Family |
|---|---|---|---|---|
| AKT1 | v-akt murine thymoma viral oncogene homologue 1 | −6.53 | Cytoplasm | kinase |
| ARHGEF7 | Rho guanine nucleotide exchange factor 7 | −4.24 | Cytoplasm | other |
| BCL2L1 | BCL2 like 1 | −9.72 | Cytoplasm | other |
| CCND1 | cyclin D1 | −10.69 | Nucleus | transcription regulator |
| E2F1 | E2F transcription factor 1 | −4.58 | Nucleus | transcription regulator |
| HRAS | Harvey rat sarcoma viral oncogene homologue | −5.69 | Plasma Membrane | enzyme |
| KCNH2 | potassium voltage-gated channel subfamily H member 2 | −3.53 | Plasma Membrane | ion channel |
| PIK3C2A | phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha | −13.45 | Cytoplasm | kinase |
| SHC1 | SHC (Src homology two domain containing) transforming protein 1 | −9.19 | Cytoplasm | other |
| SOS1 | SOS Ras/Rac guanine nucleotide exchange factor 1 | −6.55 | Cytoplasm | other |
| SPP1 | Secreted phosphoprotein 1 | −5.67 | Extracellular Space | cytokine |
CC, cumulus cells.